On Tuesday, Cartesian Therapeutics Inc (NASDAQ: RNAC) was 7.26% up from the session before settling in for the closing price of $6.47. A 52-week range for RNAC has been $5.98 – $20.12.
During the last 5-year period, the sales growth of Healthcare Sector giant was 34.24%. When this article was written, the company’s average yearly earnings per share was at 49.13%. With a float of $9.42 million, this company’s outstanding shares have now reached $26.00 million.
Cartesian Therapeutics Inc (RNAC) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cartesian Therapeutics Inc stocks. The insider ownership of Cartesian Therapeutics Inc is 63.78%, while institutional ownership is 19.49%. The most recent insider transaction that took place on Dec 04 ’25, was worth 205,797. In this transaction Director of this company bought 30,000 shares at a rate of $6.86, taking the stock ownership to the 54,366 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Former Affiliate proposed sale 26,935 for $7.15, making the entire transaction worth $192,585.
Cartesian Therapeutics Inc (RNAC) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.59 earnings per share (EPS) during the time that was better than consensus figure (set at -0.83) by 0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.57% during the next five years compared to 34.24% growth over the previous five years of trading.
Cartesian Therapeutics Inc (NASDAQ: RNAC) Trading Performance Indicators
You can see what Cartesian Therapeutics Inc (RNAC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 13.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -52.64, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -3.33 in one year’s time.
Technical Analysis of Cartesian Therapeutics Inc (RNAC)
Looking closely at Cartesian Therapeutics Inc (NASDAQ: RNAC), its last 5-days average volume was 0.22 million, which is a jump from its year-to-date volume of 0.1 million. As of the previous 9 days, the stock’s Stochastic %D was 13.39%.
During the past 100 days, Cartesian Therapeutics Inc’s (RNAC) raw stochastic average was set at 15.31%, which indicates a significant decrease from 19.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.62 in the past 14 days, which was higher than the 0.61 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.66, while its 200-day Moving Average is $10.28. However, in the short run, Cartesian Therapeutics Inc’s stock first resistance to watch stands at $7.16. Second resistance stands at $7.38. The third major resistance level sits at $7.76. If the price goes on to break the first support level at $6.56, it is likely to go to the next support level at $6.18. Now, if the price goes above the second support level, the third support stands at $5.96.
Cartesian Therapeutics Inc (NASDAQ: RNAC) Key Stats
There are 26,004K outstanding shares of the company, which has a market capitalization of 180.46 million. As of now, sales total 38,910 K while income totals -77,420 K. Its latest quarter income was 450 K while its last quarter net income were -35,900 K.
